Neuroscience
Rapid Eye Movement Sleep Behavior Disorder
100%
Rapid Eye Movement Sleep
98%
Behavior Disorder
95%
Fluorine-18
68%
Parkinson's Disease
63%
DOPA
45%
Positron Emission Tomography
42%
Dopaminergic
34%
Donepezil
30%
Cholinergic
28%
N(g) Methylarginine
27%
Nitric Oxide
27%
Aquaporin 4 Antibody
27%
Neuromyelitis Optica
27%
Dementia with Lewy Bodies
20%
Putamen
20%
Positron Emission Tomography
19%
Multiple Sclerosis
18%
In Vivo
17%
Relapsing Remitting Multiple Sclerosis
16%
Iodine-123
16%
Parkinsonism
15%
Cannabinoid
13%
Ocrelizumab
13%
Substantia innominata
13%
Optic Neuritis
13%
Brain Ischemia
13%
Adjuvant Therapy
13%
Angiotensin Receptor
13%
Meta-Analysis
13%
Rituximab
13%
Cuneus
13%
Secondary Progressive Multiple Sclerosis
13%
Cognitive Disorders
12%
Polysomnography
12%
Cognitive Function
11%
Nabiximols
11%
Locus Coeruleus
11%
Substantia nigra
11%
Synuclein
10%
Montreal Cognitive Assessment
10%
Thalamus
10%
L-DOPA
10%
Placebo
9%
Magnetic Resonance Imaging
9%
Microglia
9%
TLR 4
9%
CD163
9%
Candesartan
8%
Angiotensin II
8%
Medicine and Dentistry
Multiple Sclerosis
62%
Rapid Eye Movement Sleep Behavior Disorder
59%
Fluorine-18
43%
Parkinson's Disease
42%
Parasomnia
40%
Placebo
35%
Cannabinoid
29%
Neuropathic Pain
27%
Spasticity
27%
Medicine
27%
Case-Control Study
27%
Neuromyelitis Optica
27%
Symptom
22%
Spinal Cord Injury
21%
Quality of Life
21%
Cannabis
20%
Carbon 11
19%
DOPA
19%
N Sec Butyl 1 (2 Chlorophenyl) N Methyl 3 Isoquinolinecarboxamide C 11
18%
Nabiximols
18%
Disease
18%
Randomized Controlled Trial
17%
Diffuse Lewy Body Disease
17%
Positron Emission Tomography
16%
Iodine 123
16%
Donepezil
16%
Putamen
16%
Neuroinflammation
16%
Aquaporin 4 Antibody
16%
Effects of Cannabis
15%
Dronabinol
15%
Cannabidiol
14%
Nitric Oxide
13%
Sodium Retention
13%
Intestine Function
13%
Steroid Treatment
13%
Essential Hypertension
13%
Meta-Analysis
13%
Optic Neuritis
13%
Multimodality Imaging
13%
Recurrence Risk
13%
Disease Activity
13%
Pediatrics
13%
Tetrahydrocannabinol
12%
Psychological Well-Being
11%
Polysomnography
11%
Gastrointestinal Transit
10%
Constipation
10%
Positron Emission Tomography
10%
Levodopa
10%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
62%
Multiple Sclerosis
44%
Cannabis
40%
Spasticity
32%
Neuropathic Pain
30%
Cannabinoid
29%
Myelooptic Neuropathy
27%
Glutathione Transferase Alpha
27%
Parasomnia
27%
Disease
25%
Cannabidiol
22%
Nabiximols
21%
Spinal Cord Injury
21%
Tetrahydrocannabinol
20%
Pharmacodynamics
18%
Pharmacokinetics
18%
Symptom
16%
Aquaporin 4 Antibody
16%
Prevalence
16%
Dronabinol
15%
Normal Human
13%
Vasopressin
13%
Controlled Clinical Trial
13%
Ibuprofen
13%
Essential Hypertension
13%
Optic Neuritis
13%
Parkinson's Disease
13%
Nitric Oxide
13%
Etodolac
13%
Renin
13%
Constipation
10%
Candesartan Hexetil
8%
Side Effect
7%
Analgesic Agent
6%
Diffuse Lewy Body Disease
5%
Pharmacodynamic Parameter
5%
Pharmacokinetic Parameter
5%
Life Expectancy
5%